Drug intelligence / Profile preview

coladonin

Development stage: Preclinical
Modality: Small Molecules

Overview

Coladonin is a natural sesquiterpene coumarin ether isolated from plants such as *Ferula tunetana* and *Ferulago campestris*. It is primarily recognized as a selective inhibitor of human carbonic anhydrases IX (hCA IX) and XII (hCA XII), which are key enzymes involved in pH regulation within the hypoxic tumor microenvironment. Due to this activity, coladonin and its derivatives are being investigated as potential therapeutic agents for melanoma and glioblastoma. Furthermore, the compound has shown inhibitory effects on acetylcholinesterase and alpha-amylase, suggesting potential utility in treating neurological disorders like Alzheimer's disease and metabolic conditions such as type II diabetes mellitus.

Other names: coladonin

Targets

CA12 (Carbonic anhydrase XII)AMY (Pancreatic alpha-amylase)AcetylcholinesteraseCA9 (Carbonic anhydrase IX)

Beyond the preview

Go deeper on coladonin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on coladonin.

Explore the full profile